Ultragenyx Pharmaceutical Inc. (RARE) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
RARE's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
RARE Revenue Analysis (2013–2024)
As of February 28, 2026, Ultragenyx Pharmaceutical Inc. (RARE) generated trailing twelve-month (TTM) revenue of $630.6 million, reflecting strong growth of +14.7% year-over-year. The most recent quarter (Q3 2025) recorded $159.9 million in revenue, down 3.9% sequentially.
Looking at the longer-term picture, RARE's 5-year compound annual growth rate (CAGR) stands at +40.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $560.2 million in 2024, representing a new all-time high.
Revenue diversification analysis shows RARE's business is primarily driven by Product (51%), and Royalty (49%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and ASND (+97.4% YoY), RARE has underperformed the peer group in terms of revenue growth. Compare RARE vs AGIO →
Peer Comparison
Compare RARE's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RARECurrent | $631M | +14.7% | +40.1% | -95.7% | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| VRTX | $12.0B | +10.4% | +14.1% | 39.1% | |
| ASND | $692M | +97.4% | +150.9% | -18.9% | |
| BBIO | $502M | +126.3% | +127.4% | -113.3% | |
| BMRN | $3.2B | +12.9% | - | 16.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $560.2M | +29.0% | $483.5M | 86.3% | $-535,973,000 | -95.7% |
| 2023 | $434.2M | +19.5% | $389.0M | 89.6% | $-569,208,000 | -131.1% |
| 2022 | $363.3M | +3.4% | $335.0M | 92.2% | $-648,919,000 | -178.6% |
| 2021 | $351.4M | +29.7% | $335.4M | 95.4% | $-381,737,000 | -108.6% |
| 2020 | $271.0M | +161.3% | $264.9M | 97.7% | $-330,116,000 | -121.8% |
| 2019 | $103.7M | +101.4% | $94.7M | 91.3% | $-424,173,000 | -409.0% |
| 2018 | $51.5M | +1871.5% | $50.3M | 97.8% | $-371,373,000 | -721.2% |
| 2017 | $2.6M | +1863.9% | $2.6M | 100.0% | $-328,942,000 | -12593.5% |
| 2016 | $133K | - | $-183,071,000 | -137647.4% | $-248,007,000 | -186471.4% |
| 2015 | $0 | - | $-1,384,000 | - | $-147,738,000 | - |
See RARE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RARE Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RARE vs AGIO
See how RARE stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RARE's revenue growth accelerating or slowing?
RARE maintains +14.7% revenue growth, in line with its 5-year CAGR of +40.1%. TTM revenue stands at $631M. Growth rate remains consistent with historical average.
What is RARE's long-term revenue growth rate?
Ultragenyx Pharmaceutical Inc.'s 5-year revenue CAGR of +40.1% reflects the sustained expansion pattern. Current YoY growth of +14.7% is near this long-term average.
How is RARE's revenue distributed by segment?
RARE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.